Industry Growth Insights published a new data on “Active Pharma Ingredient Market”. The research report is titled “Active Pharma Ingredient Market research by Types (Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients), By Applications (Oncology, Cardiovascular Disease, Diabetes, Central Nervous System and Neurological Disorders, Endocrinology, Other Therapeutic Applications), By Players/Companies Teva, Novartis, Pfizer, Johnson & Johnson, Mylan, North China Pharmaceutical Group, Dr. Reddy’s Laboratories, Roche, Aurobindo pharma, Sun Pharmaceutical Industries, Boehringer Ingelheim GmbH, Bayer, BASF, DSM, Zhejiang Medicine, Biocon, Johnson Matthey, Hisun Pharmacy, Cambrex, Shandong Xinhua Pharmaceutical, Lonza group, Huahai Pharmaceutical, Haerbin Pharmaceutical Group, Cipla, Tian Yao, Lupin, North East Pharmaceutical, Albemarle, Shandong Lukang Pharmaceutical, Jiangsu Hengrui Medicine”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Active Pharma Ingredient Market Research Report
By Type
Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients
By Application
Oncology, Cardiovascular Disease, Diabetes, Central Nervous System and Neurological Disorders, Endocrinology, Other Therapeutic Applications
By Companies
Teva, Novartis, Pfizer, Johnson & Johnson, Mylan, North China Pharmaceutical Group, Dr. Reddy’s Laboratories, Roche, Aurobindo pharma, Sun Pharmaceutical Industries, Boehringer Ingelheim GmbH, Bayer, BASF, DSM, Zhejiang Medicine, Biocon, Johnson Matthey, Hisun Pharmacy, Cambrex, Shandong Xinhua Pharmaceutical, Lonza group, Huahai Pharmaceutical, Haerbin Pharmaceutical Group, Cipla, Tian Yao, Lupin, North East Pharmaceutical, Albemarle, Shandong Lukang Pharmaceutical, Jiangsu Hengrui Medicine
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Active Pharma Ingredient Market Report Segments:
The global Active Pharma Ingredient market is segmented on the basis of:
Types
Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Cardiovascular Disease, Diabetes, Central Nervous System and Neurological Disorders, Endocrinology, Other Therapeutic Applications
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Novartis
- Pfizer
- Johnson & Johnson
- Mylan
- North China Pharmaceutical Group
- Dr. Reddy’s Laboratories
- Roche
- Aurobindo pharma
- Sun Pharmaceutical Industries
- Boehringer Ingelheim GmbH
- Bayer
- BASF
- DSM
- Zhejiang Medicine
- Biocon
- Johnson Matthey
- Hisun Pharmacy
- Cambrex
- Shandong Xinhua Pharmaceutical
- Lonza group
- Huahai Pharmaceutical
- Haerbin Pharmaceutical Group
- Cipla
- Tian Yao
- Lupin
- North East Pharmaceutical
- Albemarle
- Shandong Lukang Pharmaceutical
- Jiangsu Hengrui Medicine
Highlights of The Active Pharma Ingredient Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Innovative Active Pharmaceutical Ingredients
- Generic Active Pharmaceutical Ingredients
- By Application:
- Oncology
- Cardiovascular Disease
- Diabetes
- Central Nervous System and Neurological Disorders
- Endocrinology
- Other Therapeutic Applications
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Active Pharma Ingredient Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Active pharmaceutical ingredients (API) are the active ingredients in prescription and over-the-counter medications. They are responsible for the therapeutic effects of these medications.
Some of the major players in the active pharma ingredient market are Teva, Novartis, Pfizer, Johnson & Johnson, Mylan, North China Pharmaceutical Group, Dr. Reddy¢â‚¬â„¢s Laboratories, Roche, Aurobindo pharma, Sun Pharmaceutical Industries, Boehringer Ingelheim GmbH, Bayer, BASF, DSM, Zhejiang Medicine, Biocon, Johnson Matthey, Hisun Pharmacy, Cambrex, Shandong Xinhua Pharmaceutical, Lonza group, Huahai Pharmaceutical, Haerbin Pharmaceutical Group, Cipla, Tian Yao, Lupin, North East Pharmaceutical, Albemarle, Shandong Lukang Pharmaceutical, Jiangsu Hengrui Medicine.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Active Pharma Ingredient Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Active Pharma Ingredient Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Active Pharma Ingredient Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Active Pharma Ingredient Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Active Pharma Ingredient Market Size & Forecast, 2018-2028
4.5.1 Active Pharma Ingredient Market Size and Y-o-Y Growth
4.5.2 Active Pharma Ingredient Market Absolute $ Opportunity
Chapter 5 Global Active Pharma Ingredient Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Active Pharma Ingredient Market Size Forecast by Type
5.2.1 Innovative Active Pharmaceutical Ingredients
5.2.2 Generic Active Pharmaceutical Ingredients
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Active Pharma Ingredient Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Active Pharma Ingredient Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Cardiovascular Disease
6.2.3 Diabetes
6.2.4 Central Nervous System and Neurological Disorders
6.2.5 Endocrinology
6.2.6 Other Therapeutic Applications
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Active Pharma Ingredient Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Active Pharma Ingredient Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Active Pharma Ingredient Analysis and Forecast
9.1 Introduction
9.2 North America Active Pharma Ingredient Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Active Pharma Ingredient Market Size Forecast by Type
9.6.1 Innovative Active Pharmaceutical Ingredients
9.6.2 Generic Active Pharmaceutical Ingredients
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Active Pharma Ingredient Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Cardiovascular Disease
9.10.3 Diabetes
9.10.4 Central Nervous System and Neurological Disorders
9.10.5 Endocrinology
9.10.6 Other Therapeutic Applications
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Active Pharma Ingredient Analysis and Forecast
10.1 Introduction
10.2 Europe Active Pharma Ingredient Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Active Pharma Ingredient Market Size Forecast by Type
10.6.1 Innovative Active Pharmaceutical Ingredients
10.6.2 Generic Active Pharmaceutical Ingredients
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Active Pharma Ingredient Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Cardiovascular Disease
10.10.3 Diabetes
10.10.4 Central Nervous System and Neurological Disorders
10.10.5 Endocrinology
10.10.6 Other Therapeutic Applications
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Active Pharma Ingredient Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Active Pharma Ingredient Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Active Pharma Ingredient Market Size Forecast by Type
11.6.1 Innovative Active Pharmaceutical Ingredients
11.6.2 Generic Active Pharmaceutical Ingredients
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Active Pharma Ingredient Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Cardiovascular Disease
11.10.3 Diabetes
11.10.4 Central Nervous System and Neurological Disorders
11.10.5 Endocrinology
11.10.6 Other Therapeutic Applications
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Active Pharma Ingredient Analysis and Forecast
12.1 Introduction
12.2 Latin America Active Pharma Ingredient Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Active Pharma Ingredient Market Size Forecast by Type
12.6.1 Innovative Active Pharmaceutical Ingredients
12.6.2 Generic Active Pharmaceutical Ingredients
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Active Pharma Ingredient Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Cardiovascular Disease
12.10.3 Diabetes
12.10.4 Central Nervous System and Neurological Disorders
12.10.5 Endocrinology
12.10.6 Other Therapeutic Applications
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Active Pharma Ingredient Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Active Pharma Ingredient Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Active Pharma Ingredient Market Size Forecast by Type
13.6.1 Innovative Active Pharmaceutical Ingredients
13.6.2 Generic Active Pharmaceutical Ingredients
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Active Pharma Ingredient Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Cardiovascular Disease
13.10.3 Diabetes
13.10.4 Central Nervous System and Neurological Disorders
13.10.5 Endocrinology
13.10.6 Other Therapeutic Applications
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Active Pharma Ingredient Market: Competitive Dashboard
14.2 Global Active Pharma Ingredient Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Novartis
14.3.3 Pfizer
14.3.4 Johnson & Johnson
14.3.5 Mylan
14.3.6 North China Pharmaceutical Group
14.3.7 Dr. Reddy’s Laboratories
14.3.8 Roche
14.3.9 Aurobindo pharma
14.3.10 Sun Pharmaceutical Industries
14.3.11 Boehringer Ingelheim GmbH
14.3.12 Bayer
14.3.13 BASF
14.3.14 DSM
14.3.15 Zhejiang Medicine
14.3.16 Biocon
14.3.17 Johnson Matthey
14.3.18 Hisun Pharmacy
14.3.19 Cambrex
14.3.20 Shandong Xinhua Pharmaceutical
14.3.21 Lonza group
14.3.22 Huahai Pharmaceutical
14.3.23 Haerbin Pharmaceutical Group
14.3.24 Cipla
14.3.25 Tian Yao
14.3.26 Lupin
14.3.27 North East Pharmaceutical
14.3.28 Albemarle
14.3.29 Shandong Lukang Pharmaceutical
14.3.30 Jiangsu Hengrui Medicine
